4D Molecular Therapeutics Reports Increased Q1 Losses Amidst Accelerated Clinical Progress for Lead Gene Therapy Candidate

summarizeSummary

4D Molecular Therapeutics reported increased Q1 2026 net losses due to higher R&D spending on its lead gene therapy, 4D-150, which achieved accelerated Phase 3 enrollment and positive interim data. The company continues to fund operations through dilutive offerings and a collaboration with Otsuka, while its CEO adopted a 10b5-1 selling plan.

check_boxKey Events · Earnings and Guidance · FDMT

• Increased Net Loss and R&D Expenses

  Net loss for the three months ended March 31, 2026, increased to $68.8 million from $48.0 million in the prior-year period, primarily due to a 60% increase in research and development expenses to $65.0 million, driven by advanced clinical trial activity for 4D-150.

• Accelerated Clinical Progress for 4D-150

  Enrollment for the 4D-150 4FRONT-1 Phase 3 trial in wet AMD was completed ahead of initial projections, with topline data expected in the first half of 2027. Positive long-term interim results from the PRISM Phase 1/2 trial in wet AMD and SPECTRA trial in DME were also reported, demonstrating consistent and durable benefits.

• Collaboration Revenue from Otsuka Pharmaceutical

  Collaboration and license revenue significantly increased to $3.0 million in Q1 2026, primarily from the Otsuka Pharmaceutical Co., Ltd. agreement for 4D-150, which includes an $85.0 million upfront payment received in Q4 2025 and ongoing cost-sharing.

• Ongoing Capital Raising and Dilution

  The company raised $9.7 million in net proceeds through its At-The-Market (ATM) offering program in Q1 2026 by selling 1,012,145 shares. Additionally, 6,600,000 shares were exchanged for pre-funded warrants in January 2026, and an additional 3,880,394 shares were authorized for equity incentive plans, indicating continued share dilution.

auto_awesomeAnalysis · FDMT · Life Sciences

4D Molecular Therapeutics, a late-stage biotechnology company, reported an increased net loss for Q1 2026, primarily driven by a significant rise in research and development (R&D) expenses as it advances its lead gene therapy candidate, 4D-150. Despite the higher burn rate, the company achieved notable clinical milestones, including the early completion of enrollment for its 4D-150 4FRONT-1 Phase 3 trial in wet AMD and positive long-term interim results from earlier trials. The collaboration with Otsuka Pharmaceutical is beginning to generate revenue, providing a crucial funding stream. However, the company continues to rely on dilutive financing activities, including its at-the-market (ATM) offering and pre-funded warrant exchanges, to maintain its cash runway. The CEO's adoption of a Rule 10b5-1 trading plan for a notable number of shares is also disclosed.